Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Cook, G orcid.org/0000-0003-0223-3652, Parrish, C, Yong, K et al. (12 more authors) (2018) Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology

Metadata

Item Type:	Proceedings Paper
Authors/Creators:	Cook, G https://orcid.org/0000-0003-0223-3652 Parrish, C Yong, K Cavenagh, J Snowden, JA Drayson, MT Garg, M Cairns, D https://orcid.org/0000-0002-2338-0179 Ashcroft, J Striha, A https://orcid.org/0000-0003-3363-8417 Hockaday, A de Tute, RM Owen, RG Williams, C Cook, M
Dates:	Published: 29 November 2018
Institution:	The University of Leeds
Academic Units:	The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Funding Information:	Funder Grant number Cancer Research UK A19272
Depositing User:	Symplectic Publications
Date Deposited:	17 Feb 2020 11:18
Last Modified:	29 Jun 2020 13:36
Status:	Published
Publisher:	American Society of Hematology
Identification Number:	10.1182/blood-2018-99-112116
Related URLs:	Author
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:157101

CORE (COnnecting REpositories)

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Metadata

Download not available

Export

Statistics